Stockreport

Aptinyx Initiates Phase 2 Study of NYX-458 in Patients with Mild Cognitive Impairment Associated with Parkinson’s Disease

Aptinyx Inc.  (APTX) 
Last aptinyx inc. earnings: 3/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.aptinyx.com/investors-media
PDF Phase 2 study follows NYX-458 preclinical data demonstrating reversal of cognitive deficits in non-human primate model of Parkinson’s disease Fourth Phase 2 study initi [Read more]